Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer

Eur Urol. 2022 Dec;82(6):659. doi: 10.1016/j.eururo.2022.08.024. Epub 2022 Sep 8.

Authors

Mehraban Kavoussi¹, Ali A Nasrallah¹, Stephen B Williams²

Affiliations

¹ Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA.
² Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. Electronic address: stbwilli@utmb.edu.

PMID: 36089530
DOI: 10.1016/j.eururo.2022.08.024

No abstract available

MeSH terms

Adjuvants, Immunologic / therapeutic use
Administration, Intravesical
BCG Vaccine / therapeutic use
Bacillus*
Docetaxel / therapeutic use
Gemcitabine
Humans
Neoplasm Invasiveness
Neoplasm Recurrence, Local / drug therapy
Urinary Bladder Neoplasms* / drug therapy

Substances

Docetaxel
BCG Vaccine
Adjuvants, Immunologic
Gemcitabine